Search results for " temozolomide"

showing 5 items of 5 documents

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide

2018

Rationale: The activity of the transcription factor, hypoxia-inducible factor (HIF)-1?, is a common driver of a number of the pathways involved in the aggressiveness of glioblastomas (GBMs), and it has been suggested that the reduction in this activity observed, soon after the administration of temozolomide (TMZ), can be a biomarker of an early response in GBM models. As HIF-1? is a tightly regulated protein, studying the processes involved in its downregulation could shed new light on the mechanisms underlying GBM sensitivity or resistance to TMZ. Methods: The effect of HIF-1? silencing on cell responsiveness to TMZ was assessed in four genetically different human GBM cell lines by evaluat…

0301 basic medicineCancer Researchapoptosis; chaperone-mediated autophagy activity; hypoxia-inducible factor-1? silencing; temozolomide responsiveness; theranostic biomarkerBiologylcsh:RC254-28203 medical and health scienceshypoxia-inducible factor-1α silencing0302 clinical medicineGliomamedicineGene silencingViability assayTranscription factorOriginal Researchchaperone-mediated autophagy activityTemozolomideAutophagyapoptosismedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstheranostic biomarker030104 developmental biologyHypoxia-inducible factorsOncologyApoptosis030220 oncology & carcinogenesisCancer researchtemozolomide responsivenessmedicine.drugFrontiers in Oncology
researchProduct

Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells.

2013

The concept of a stem cell subpopulation as understood from normal epithelial tissue or bone marrow function has been extended to our understanding of cancer tissue and is now the target of treatment efforts specifically directed to this subpopulation. In glioblastoma, as well as in other cancers, increased expression of aldehyde dehydrogenase (ALDH) has been found localized within a minority sub-population of tumor cells which demonstrate stem cell properties. A separate body of research associated increased expression of heat-shock protein-90 (HSP90) with stem cell attributes. We present here results from our initial immunohistochemistry study of human glioblastoma biopsy tissue where bot…

Aldehyde dehydrogenasePharmacologyBiochemistryAldehyde dehydrogenase; Disulfiram; Glioblastoma; HSP90; Ritonavir; Stem cell; TemozolomideCancer stem cellBiopsyDisulfirammedicineTemozolomideHSP90HumansHSP90 Heat-Shock ProteinsTemozolomideRitonavirStem cellmedicine.diagnostic_testbiologyCancerGeneral MedicineAldehyde Dehydrogenasemedicine.diseaseGene Expression Regulation NeoplasticProtein Transportmedicine.anatomical_structurebiology.proteinCancer researchImmunohistochemistryBone marrowStem cellGlioblastomamedicine.drugBiochimie
researchProduct

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.

2023

Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly, a subset of MMRp CRCs contains variable fractions of MMRd cells, but it is unknown how their presence impacts immune surveillance. We asked whether modulation of the MMRd fraction in MMR heterogeneous tumors acts as an endogenous cancer vaccine by promoting immune surveillance. To test this hypothesis, we use isogenic MMRp (Mlh1+/+) and MMRd (Mlh1-/-) mouse CRC cells. MMRp/MMRd cells mixed at different ratios are injected in immunocompetent mice and tumor reje…

Cancer Research6-thioguaninemismatch repairOncology6-thioguanine; heterogeneity; immune checkpoint blockade; immune evasion; immune surveillance; microsatellite unstable tumors (MSI); mismatch repair; temozolomide6-thioguanine heterogeneity immune checkpoint blockade immune evasion immune surveillance microsatellite unstable tumors (MSI) mismatch repair temozolomideimmune surveillancemicrosatellite unstable tumors (MSI)temozolomideheterogeneityimmune checkpoint blockadeSettore MED/08 - Anatomia Patologicaimmune evasionCancer cell
researchProduct

3-CHLOROETHYL-PYRROLO[2,1-D][1,2,3,5]TETRAZINES: SYNTHESIS AND ANTITUMOR ACTIVITY

2011

TETRAZINES TEMOZOLOMIDE MITOZOLOMIDE ANTITUMOR ACTIVITYTETRAZINES; TEMOZOLOMIDE; MITOZOLOMIDE; ANTITUMOR ACTIVITYMITOZOLOMIDETEMOZOLOMIDETETRAZINESSettore CHIM/08 - Chimica FarmaceuticaANTITUMOR ACTIVITY
researchProduct

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the …

2013

Kast, Richard E. et al.

medicine.medical_specialtyCaptoprilTel avivMorpholinesArtesunateReviewGluconatesAngiotensinQuality of lifeAuranofinSertralineAntineoplastic Combined Chemotherapy ProtocolsDisulfiramTemozolomidemedicineRecurrent diseaseHumansIn patientNelfinavirTemozolomideBrain Neoplasmsbusiness.industrySuccinatesNeurokininCytotoxic chemotherapyUniversity hospitalmedicine.diseaseArtemisininsSurgeryDacarbazineKetoconazoleOncologyangiotensin aprepitant artesunate auranofin captopril cytokines disulfiram glioblastoma ketoconazole nelfinavir neurokinin sertraline temozolomideFamily medicineCytokinesNeoplasm Recurrence LocalGlioblastomabusinessAprepitantGlioblastomamedicine.drugOncotarget
researchProduct